Maravai LifeSciences Holdings, Inc. (MRVI) Stock Score, Valuation & Financial Research
Maravai LifeSciences Holdings, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 14/100.
Quick answer for MRVI
Maravai LifeSciences Holdings, Inc. currently has a Wall Street Score of 14/100. The stored market price is $6.53. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Maravai LifeSciences Holdings, Inc. does
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in
MRVI financial snapshot
- Wall Street Score:
- 14/100
- Current price:
- $6.53
- Market capitalization:
- $1.80B
- Revenue:
- $204.7M
- Net income:
- $-104.6M
- Free cash flow:
- $-70.7M
- Cash:
- $165.9M
- Total debt:
- $270.9M
- EPS:
- -0.91
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 11/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-70.7M, showing cash burn in the current stored period.
- The balance sheet shows $165.9M of cash versus $270.9M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research MRVI
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.